Video

Prostate Blood Test: Understanding the Tests

Related Videos
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Image of man with brown and grey hair.
Image of a woman with long red hair.
Image of a man with rectangular glasses and a goatee.
Image of a doctor with dark curly hair and rectangular glasses.
Dr. Kelly Stratton
Related Content
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
February 16th 2025

EBRT Regimens Show Long-Term Survival Outcomes in Prostate Cancer

Roman Fabbricatore
Patients with intermediate-risk prostate cancer had a 15-year prostate cancer–specific survival rate of 91% with EBRT, with or without short-term ADT.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of bladder.
February 14th 2025

Padcev May Be Safe in Older Patients With Bladder Cancer

Darlene Dobkowski, MA
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of the bladder.
February 13th 2025

Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume

Kyle Doherty
Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death by 46%, per ARANOTE data.
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months. | © pikovit - stock.adobe.com
February 13th 2025

Patients With Prostate Cancer Experience Temporary Urinary Function Decline After CIRT

Alex Biese
Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to normal after three months.